source
- Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increaseEntrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…
- Blackstone invests $250 million in Anagram to address cystic fibrosis complicationBlackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…